Akkermansia muciniphila was isolated from human faeces. It is a species of human intestinal mucin-degrading bacterium. It is a Gram-negative, strictly anaerobic, non-motile, non-spore-forming, oval-shaped bacterium.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
CAT
Size
Price
Quantity
LBGF-0722-GF48
Product Information
Product Overview
Akkermansia muciniphila was isolated from human faeces. It is a species of human intestinal mucin-degrading bacterium. It is a Gram-negative, strictly anaerobic, non-motile, non-spore-forming, oval-shaped bacterium.
Target
Akkermansia
Genus
Akkermansia
Strain Designation
WB-STR-0001
Application
Study and research
Culture Medium
Chocolate agar
Culture Conditions
37°C; Anaerobic
Risk Group
1
Product Format
Freeze-dried
Packaging
Ampoule tube
Storage
-80°C
Shelf Life
6 years
Target Introduction
Introduction
Akkermansia is a genus in the phylum Verrucomicrobia; Bacteria with the type species Akkermansia muciniphila. Among the next-generation beneficial microbes that have been identified, Akkermansia muciniphila is a promising candidate. Akkermansia muciniphila is a strict anaerobe recently isolated from human faeces and uses the mucin as thesole sources of carbon and nitrogen elements. Due to this unique function and its high universality and richness in almost all life stages, Akkermansia muciniphila opened new avenues for the application in next-generation therapeutic probiotic. It is a bacterium of oval shape, non-motile and Gram-negative andforms no endospores and widely distributed in the intestines of human and animals. Akkermansia muciniphila is one of the normal gutsymbionts throughout our life. Currently, a large number of researches on Akkermansia muciniphila mainly focused on explaining its relationship with diseases. It promises to be a therapeutic target in the microbiota-related diseases, such as colitis, metabolic syndrome, immune diseases and cancer. Preliminary human datasuggest oral administration of Akkermansia muciniphila safe, butits effect needs to be further verified in more human clinical trials in the near future.
Alternative Names
Akkermansia muciniphila
FAQs Customer Reviews Related Products
What is Akkermansia muciniphila and where is it typically found?
Akkermansia muciniphila is an anaerobic, Gram-negative bacterium that resides in the human gut, particularly within the mucus layer. It was first identified in 2004 and constitutes about 3% of the human gut microbiota. This bacterium plays a key role in maintaining intestinal health by breaking down mucins, which strengthens the gut barrier and supports overall immune function.
How is Akkermansia muciniphila cultivated in laboratory settings for research?
Due to its anaerobic nature, Akkermansia muciniphila requires specialized conditions for cultivation. It is typically grown in an anaerobic chamber with a mucin-rich medium that supports its growth. Researchers must ensure careful control of environmental conditions, such as temperature and oxygen levels, to maintain optimal growth for experimental applications.
How does Akkermansia muciniphila influence gut barrier function in research models?
Akkermansia muciniphila has been found to increase the number of goblet cells, which are responsible for secreting mucins, thereby enhancing mucus production and maintaining gut integrity. This bacterium plays a vital role in protecting the gut barrier, particularly in conditions such as colitis, where mucus production may be impaired.
Can Akkermansia muciniphila be genetically engineered for research purposes?
Yes, there is ongoing research exploring the genetic engineering of Akkermansia muciniphila to enhance its therapeutic potential. Some studies have focused on modifying its outer membrane proteins to develop targeted therapies for conditions like colorectal cancer and metabolic disorders. These engineered strains show promise for delivering specific therapeutic benefits
What is the impact of Akkermansia muciniphila on the immune system in animal models?
In studies involving animal models, Akkermansia muciniphila has been shown to modulate immune responses by interacting with mucosal surfaces. It promotes the expression of anti-inflammatory cytokines and can help regulate immune homeostasis in the gut. This interaction is crucial for understanding its role in treating diseases like inflammatory bowel disease and obesity.
Exceptional Performance in Gut Microbiome Research
The Akkermansia muciniphila strain from Creative Biolabs outperformed competitors in our gut microbiome research, offering consistent and reliable data crucial for drug development.
Outstanding Quality for Metabolic Disease Studies
Creative Biolabs' Akkermansia muciniphila was essential in our metabolic disease studies. Its purity and consistency made it superior to other sources we've tested.
Unmatched Efficacy in Inflammation Research
We used Creative Biolabs' Akkermansia muciniphila in inflammation models, and it exceeded expectations. Its impact on gut barrier function was exceptional compared to other strains.
Reliable for Obesity-Related Research
In our research on obesity-related therapies, Creative Biolabs' Akkermansia muciniphila stood out. Its high reproducibility and efficacy made it a top choice for our studies.
Perfect for Immunotherapy Research
For immunotherapy research, the Akkermansia muciniphila from Creative Biolabs was indispensable. Its quality and stability made a noticeable difference in immune response studies.
Click the button below to contact us or submit your feedback about this product.
